date:Jul 31, 2014
D 4.4 cents per share) excluding the effects of revaluing biological assets under IAS 41. EBITDA, excluding the effects of revaluing biological assets under IAS 41, of USD 115.8 million (H1 2013: USD 54.2 million). EBITDA, excluding the effects of revaluing biological assets and net foreign exchange gains/(losses), of USD 112.8 million (H1 2013: USD 68.4 million). Gross margin of 42.2% (H1 2013: 32.8%) reflecting higher selling prices coupled with cash cost reductions and the depreciation of the